Raymond C. Bergan, MD
Fred and Pamela Buffett Cancer Center
Professor of Medicine
Academic office mailing address:
UNMC Eppley Cancer Center
986805 Nebraska Medical Center
Omaha, NE 68198-6805
|1979-1983||Bachelors of Science in Biochemistry - State University of New York at Buffalo|
|1983-1987||Doctor of Medicine- State University of New York Health Science Center at Syracuse|
|1987-1990||Internship and Residency in Internal Medicine- State University of New York Health Science Center at Syracuse|
|1990-1993||Fellowship in Medical Oncology Medicine Branch- National Cancer Institute, National Institutes of Health|
|1993-1998||Research Fellowship in Drug Discovery, Clinical Pharmacology Branch and Medicine Branch- National Cancer Institute, National Institutes of Health|
|2011-2015||Leadership Development Course- Harvard T.H. Chan School of Public Health|
Raymond Bergan, M.D., is a physician/scientist and an internationally regarded cancer researcher known for leading breakthrough studies on how cancer cells spread and developing preventive treatments for high-risk patients.
After completing fellowships in medical oncology and drug discovery at the National Cancer Institute (NCI), Bergan joined Northwestern University, serving as the Director of Experimental Therapeutics and Leader of the Prevention Program for the Lurie Comprehensive Cancer Center. He founded and served as Director of one of only five NCI-funded Early Phase Cancer Chemoprevention Programs, expanding it to 19 leading research institutions. Under his leadership, this program has made major findings that are beginning to transform the field. These breakthroughs include demonstrating that localized delivery of drugs allows for organ-specific targeting, maintenance of efficacy, and negation of systemic toxicity. They also include proving that the impact of preventive treatment can be measured in intact epithelium, in at-risk organs, using light-based technology. This work, in turn, showed the technology’s potential to measure the effectiveness of prevention therapy in real-time at the individual patient level.
At Oregon Health & Science University, Bergan served as Chief, Division of Hematology/Oncology, Co-Leader Translational Oncology Program, and Associate Director, Knight Cancer Institute. He expanded the division by over 50% to 103 faculty, increasing new patient referrals, increasing therapeutic trials accrual by 50%, helped design two new buildings, one basic and one clinical-focused, and through these roles contributed to attaining NCI -designated Comprehensive Cancer Center status for the first time. Bergan designed and implemented the SMMART trials program, funded by an initial $15M donation. This program uses multi-omic characterization of tumors to deliver combinations of targeted therapy tailored to the biology of each individual patient. The program is designed to change how we treat cancer.
Bergan’s basic and translational research group has expanded the understanding of how cancer cells transform to travel throughout the body and how this process can be therapeutically inhibited. His group was the first to target this form of disease progression in humans. Recent work in this area by his group was cited by WIRED magazine as a “monumental achievement.” Understanding the changes that enable the spread of the disease is essential to saving lives; metastasis is a leading cause of death in cancer patients.
In other leadership roles, Bergan currently serves on two External Advisory Committees for the NCI, for their PREVENT Program, and their Early Phase Cancer Prevention Therapy Program. In prior leadership positions, he was co-founder and co-director of the Northwestern Center for Molecular Innovation and Drug Discovery, Chair, Cancer Prevention Committee for ECOG-ACRIN, a member of the NCI Cancer Prevention Steering Committee; he also served as a panelist for the NIH Director’s Scientific Management Review Board, focusing on the task of improving how NIH improves its approach to therapeutics development.
Li Xu, Many et. al., Raymond Bergan. Precision Therapeutic Targeting of Human Cancer Cell Motility. Nature Communications, 9(1):2454, 2018. PMID: 29934502; PMCID: PMC6014988
Zahi I Mitri, Many et al., Raymond C Bergan. Implementing a Comprehensive Translational Oncology Platform: From Molecular Testing to Actionability. Journal of Translational Medicine, 16(1):358-68, 2018; PMID: 30551737
Limin Zhang, Abhinandan Pattanayak, Wenqi Li, Hyun-Kyung Ko, Graham Fowler, Ryan Gordon, and Raymond C. Bergan. A Multifunctional Therapy Approach for Cancer: Targeting Raf1- Mediated Inhibition of Cell Motility, Growth, and Interaction with the Microenvironment, Molecular Cancer Therapeutics, 19(1):39-51, 2020; PMID: 31582531
Li Xu, Many et al., Raymond Bergan* and Kaichun Wu. A Phase I Trial of Berberine in Chinese with Ulcerative Colitis, (*PI of NCI funding) Cancer Prevention Research, 13(1):117-126, 2020
Dane Dickson, Jennifer Johnson, Raymond Bergan, Rebecca Owens, Vivek Subbiah, and Razelle Kurzrock. The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. Cell 2020, 180: 9-14; PMID: 31951522; Leading Edge Commentary (Editor Selected)
Dane Dickson, Jennifer Johnson, Raymond Bergan, Rebecca Owens, Vivek Subbiah, and Razelle Kurzrock. Trial Types in Precision Medicine. Cell 2020, 181: 208; doi: 10.1016/j.cell.2020.02.032; PMID: 32243791
Zhenzhen Zhang, Jeffrey Bien, Motomi Mori, Sonali Jindal, and Raymond C. Bergan. A Way Forward for Cancer Prevention Therapy: Personalized Risk Assessment, Oncotarget, 2019; 10:6898-6912. PMID: 31839883
Allen Li and Raymond Bergan. Clinical Trial Design in the Era of Big Data and Precision Medicine: Past, Present, and Future. Invited Review, Cancer, 126(22): 4838-4846, 2020; PMID: 32931022.
Additional Publications at PubMed.Gov: https://www.ncbi.nlm.nih.gov/pubmed